£3,066,771,541

Please click on the video to hear Andrew Watson discussing his initiation note on Miton. This summarises the Miton business model and the favourable outlook for AuM growth in a fund range with material capacity, underpinned

Please click on the video to hear Jo Reedman talk about Elektron Technology’s three businesses: Bulgin, Elektron Eye Technology and Checkit. She discusses the group’s strong FY18 results and encouraging start to FY19, management’s plans to

RBS has announced its intention to acquire our client FreeAgent for £53m. This is the first time since the 2008 crisis that RBS acquires a business. Quoted on AIM since November 2016 FreeAgent is a provider

Summit Therapeutics plc, the Oxford based drug discovery and development company advancing therapies for rare and infectious diseases, announced today that it has raised £15 million. The Placing, which was oversubscribed, was conducted by means of

We at N+1 Singer are very proud of our Research output and we’ve listed below some of our achievements. We are grateful for the ongoing support of our institutional clients in internal and external surveys and

Please click on the video below to hear our analysts present the main themes of their latest Pharmaceutical Services sector report.    To receive the full sector note, email enquiry@n1singer.com